Article Information
History
- January 28, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Göran Tornling1,
- Rohit Batta2,
- Joanna Porter3,
- Thomas Bengtsson4,
- Kartikeya Parmar5,
- Reema Kashiva6,
- Anders Hallberg7,
- Anne Katrine Cohrt2,
- Kate Westergaard2,
- Carl-Johan Dalsgaard2,* and
- Johan Raud2,8
- 1Respiratory Medicine Division, Department of Medicine Solna, Karolinska Institutet, SE-171 77 Stockholm, Sweden
- 2Vicore Pharma AB, Kronhusgatan 11, SE-411 05 Gothenburg, Sweden
- 3UCL Respiratory, University College London & Department of Thoracic Medicine, University College Hospitals London, London NW1 2PG, UK
- 4StatMind AB, Scheelevägen 17, SE-223 70 LUND, Sweden
- 5Department of Medicine, Nodal officer at 1200-bed COVID-19 hospital, Civil Hospital and B J Medical College, Asarwa, Ahmedabad GUJARAT, India 380016
- 6Department of Medicine, Noble Hospitals Pvt. Ltd, 153 Magarpatta City Road, Hadapsar, Pune MAHARASHTRA, India 411013
- 7Department of Medicinal Chemistry, Uppsala University, SE-751 23 Uppsala, Sweden
- 8Institute of Environmental Medicine, Karolinska Institutet, SE-171 77 Stockholm, Sweden
- ↵*Correspondence:
Carl-Johan Dalsgaard, Vicore Pharma AB, Kronhusgatan 11, SE-411 05 Gothenburg, Sweden. E-mail: carl-johan.dalsgaard{at}vicorepharma.com
Posted January 28, 2021.
The angiotensin type 2 receptor agonist C21 restores respiratory function in COVID19 - a double-blind, randomized, placebo-controlled Phase 2 trial
